Nluc Reporter Cell Line - NCI-H660

NCI-H660 is a rare and highly aggressive human prostate cancer cell line, originally derived from a lymph node metastasis of a small cell carcinoma originating in the prostate gland of a 63-year-old male patient. Exhibiting a mixed growth pattern—primarily forming floating aggregates of round cells with a minor loosely attached population—NCI-H660 serves as an essential in vitro model for neuroendocrine prostate cancer (NEPC). It is particularly noted for its androgen receptor (AR) negativity, androgen-independent proliferation, and the presence of the classic TMPRSS2-ERG gene fusion. The Nluc Reporter Cell Line - NCI-H660 elevates this critical oncological model through the stable integration of the NanoLuc (Nluc) reporter gene. NanoLuc is a highly engineered, exceptionally compact (19.1 kDa) luciferase enzyme derived from the deep-sea shrimp Oplophorus gracilirostris. When reacting with its specific substrate, furimazine, it yields an intense luminescent signal—frequently up to 100 times brighter than standard firefly luciferase. Crucially, this precise genetic modification preserves the unique growth dynamics, morphology, and complex neuroendocrine molecular signature of the parental line, providing a biologically authentic and highly sensitive platform for advanced prostate cancer research.

The integration of the ultra-bright NanoLuc reporter transforms the NCI-H660 cell line into a uniquely powerful tool for both in vitro analytics and complex preclinical animal modeling. On the laboratory bench, the intense luminescent output enables highly sensitive detection of minute cell populations, making it an ideal platform for high-throughput screening of novel targeted therapies and precise cytotoxicity assays. Because NEPC is a lethal, treatment-resistant disease lacking standard prostate-specific antigen (PSA) expression, the exceptional signal-to-noise ratio of NanoLuc is critical for dynamic tracking. In preclinical in vivo studies, implanting these reporter cells into immunodeficient mice to create localized or metastatic cell line-derived xenograft (CDX) models allows for unparalleled tracking of disease progression. The brilliant NanoLuc signal facilitates highly sensitive, non-invasive bioluminescence imaging (BLI) in living subjects. This advanced capability empowers researchers to visually map early tumor engraftment, pinpoint microscopic metastatic dissemination, and longitudinally evaluate the systemic efficacy of experimental NEPC therapeutics over extended timelines, drastically reducing the reliance on destructive endpoint analyses.